Novel Therapeutic Approaches to Improve Outcomes for Patients with PAH

AMA/ANCC/ACPE Activity
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.
Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of multifactorial etiology. Currently, therapies for treating pulmonary hypertension have been used alone and in combination to demonstrate improvements in quality of life and hemodynamic parameters as well as in slowing disease progression; however, beneficial effects on survival are limited. None offer a cure against PAH nor directly address the underlying cellular proliferation that leads to increased pulmonary arterial pressure, and the median survival rate remains at 61% at five years after diagnosis. Extensive research efforts have led to the emergence of innovative therapeutic approaches in PAH. This on-demand webcast focuses on several important aspects of PAH management, including a discussion of the challenges diagnosing and treating patients, clinical trial data on emerging therapeutics for the management of PAH, and a review of strategies to optimize outcomes for patients with PAH.
FACULTY
Aaron Waxman, MD, PhD, FACP, FCCP
Director, Pulmonary Vascular Disease Program
Executive Director, Center for Pulmonary Heart Diseases
Brigham and Women's Hospital, Heart and Vascular Center
Mardi Gomberg-Maitland, MD, MSc
Chief Research Officer
George Washington Office of Clinical Research
Director, Pulmonary Hypertension
George Washington University School of Medicine and Health Sciences
Review the activity at bit.ly/3y4oAXr and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.
This activity is provided in collaboration with Rush University Medical Center and Practice Point Communications
Supported by independent educational grants from
Merck Sharp & Dohme LLC a subsidiary of Merck & Co., Inc.